Christopher Han

Rutgers, The State University of New Jersey

Papers

Total Citations

H-Index

About

Christopher Han is a urologic researcher whose work bridges clinical biomarkers and surgical innovation in genitourinary oncology. His most impactful contribution, "Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer" (2015, 50 citations), introduced a practical, non-invasive tool for risk stratification—helping clinicians identify which low-risk prostate cancer patients may safely avoid aggressive treatment. This work has influenced the growing field of active surveillance by leveraging routine blood counts as prognostic indicators. Han also advanced the understanding of rare renal malignancies through his case report on renal leiomyosarcoma (2015, 16 citations), providing critical clinical guidance for a poorly understood tumor. Additionally, his state-of-the-art review on laparoscopic partial nephrectomy (2014) synthesized evolving surgical techniques for small renal masses, documenting the paradigm shift from radical to nephron-sparing surgery. With a focused portfolio spanning biomarker-driven risk assessment, rare tumor pathology, and minimally invasive surgical outcomes, Han’s research offers practical tools for urologists managing prostate and kidney cancers, demonstrating how laboratory values and surgical innovation can together improve patient stratification and treatment decisions.